Compounded Tirzepatide: Where Things Stand in July 2026 A quick, dated note, since plenty of people following this chart are using compounded versions
By late 2025 that had doubled to 12%
Mediation analysis from the STEP trials found that of the additional 7.6-14.4% weight loss achieved with semaglutide versus placebo, less than 1 percentage point was mediated by gastrointestinal adverse events
Three semaglutide medications are currently approved by the FDA: Wegovy is approved for weight loss treatment, and can be prescribed to adults and children 12 and older with obesity, as well as some adults with overweight who also have weight-related health problems, such as high blood pressure
Without adequate GSH to replenish NADPH, low NADPH levels result directly in increased ROS which can damage mitochondria, DNA, and other important cellular components [24,25]